Chester County News and Community Website
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has announced that the first patient has been dosed in its Phase 2/3 GARDian3 clinical trial evaluating OCU410ST, a gene therapy candidate designed …
Ocugen Doses First Patient in Pivotal Trial for Stargardt Gene Therapy Read More
KING OF PRUSSIA, PA — XyloCor Therapeutics has dosed the first patient in its Phase 2b EXACT-2 trial evaluating XC001 (encoberminogene rezmadenovec), a novel gene therapy designed to help patients …
XyloCor Doses First Patient in Pivotal Gene Therapy Trial for Refractory Angina Read More
WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) has announced an amended collaboration and licensing agreement with Torii Pharmaceutical Co. Ltd. to initiate a global Phase 3 clinical trial …
Verrica Pharmaceuticals Advances Global Phase 3 Trial for YCANTH with Amended Torii Agreement Read More
RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) has announced the publication of groundbreaking results from its pivotal Phase 3 Launch-HTN trial in the Journal of the American Medical Association …
Mineralys Therapeutics Publishes Phase 3 Trial Results in JAMA for Hypertension Treatment Read More
WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) has achieved a major milestone in its Phase 2 SEISMiC C study, announcing the planned enrollment of 20 patients for its interim …
Windtree Therapeutics Advances Istaroxime Phase 2 Study with Interim Analysis Enrollment Read More
DOYLESTOWN, PA — Metabolics Pharma has announced preclinical findings highlighting the unique benefits of its drug candidate, ENT-03, in treating obesity and related metabolic dysfunctions. The study revealed that ENT-03 …
Metabolics Pharma’s ENT-03 Shows Promise in Obesity Treatment Read More
DOYLESTOWN, PA — Metabolics Pharma has announced top-line results from a Phase 1a clinical trial of ENT-03, its investigational drug for obese and diabetic patients. The trial demonstrated that ENT-03 …
Metabolics Pharma Reports Promising Phase 1a Results for ENT-03 Read More
SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) has unveiled new data demonstrating the efficacy of IMAAVY™ (nipocalimab-aahu) for the treatment of generalized myasthenia gravis (gMG). Presented at the …
Johnson & Johnson Highlights Promising Data on IMAAVY™ for Generalized Myasthenia Gravis Read More
WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) has successfully completed enrollment in the Phase 3 SELVA clinical trial of QTORIN™ 3.9% rapamycin anhydrous gel, a potential breakthrough treatment for …
Palvella Therapeutics Announces Completion of Phase 3 SELVA Trial for QTORIN Rapamycin Read More
PHILADELPHIA, PA — Passage Bio, Inc. (NASDAQ: PASG) has announced encouraging updates from the ongoing Phase 1/2 upliFT-D clinical trial for PBFT02, a one-time gene therapy for frontotemporal dementia (FTD) …
Passage Bio Reports Progress in Gene Therapy for Frontotemporal Dementia Read More